Results 171 to 180 of about 54,819 (268)

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey   +7 more
wiley   +1 more source

Land use-induced soil carbon loss in the dry tropics nearly offsets gains in northern lands. [PDF]

Nat Commun
Wang H, Ciais P, Yang H, Smith P, Grassi G, Schwingshackl C, Panagos P, Bar-On Y, Sitch S, Chevallier F, Palmer PI, Li X, Hong S, Chang J, Albergel C, Fan L, Wang K, Liu L, Frappart F, Wigneron JP.   +19 more
europepmc   +1 more source

MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Aminoglycosides are broad‐spectrum antibiotics used in the management of severe infections. Aminoglycosides are associated with nephrotoxicity and ototoxicity. Although dosing strategies such as once‐daily administration and therapeutic drug monitoring have reduced the incidence of nephrotoxicity, ototoxicity remains unpredictable and may occur at ...
John H. McDermott, Sian Hilton, Cinzia Dello Russo, Nicola Booth, Simon Drysdale, Philip Howard, Stephen Hughes, Mallinath Chakraborty, Helen McDevitt, Charlotte Alston, Maya Desai, Mike Beadsworth, Adam Reynolds, Serim Min, Katherine Payne, Munir Pirmohamed, William G. Newman   +16 more
wiley   +1 more source

A Global Analysis of the Distribution Patterns of Style-Length Polymorphisms Across Angiosperms. [PDF]

Ecol Evol
Rodrigues Novaes L, Simón-Porcar V, Molina-Venegas R, Arroyo J.   +3 more
europepmc   +1 more source

Tropical Diabetes? [PDF]

Tropical Doctor, 1996
openaire   +2 more sources

Pharmacometric evaluation of pre‐referral rectal artesunate in children with severe malaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Parenteral artesunate is the preferred first‐line treatment for severe malaria. Pre‐referral rectal artesunate suppositories are recommended where parenteral treatment is inaccessible. In this study, we compared dihydroartemisinin exposure and model‐predicted early parasite clearance following rectal artesunate and intravenous artesunate in ...
Ayorinde Adehin, Marie A. Onyamboko, Caterina Fanello, Nicholas J. White, Nicholas P. J. Day, Richard M. Hoglund, Joel Tarning   +6 more
wiley   +1 more source

Validation and design of a wearable harness for monitoring remote heart rate variability in dairy cows under grazing conditions. [PDF]

Trop Anim Health Prod
Betancourth-Chaves P, Montoya-Zuluaga J, Rodríguez B, Timarán-Rivera A, Ríos-Peña L, Hernández-Oviedo F, Vallejo-Timarán D.   +6 more
europepmc   +1 more source

Dataset of a kilometer-scale meso-NH simulation for C2OMODO: The RCElarge300 collection of MesoNHforC2OMODO. [PDF]

Data Brief
Chaboureau JP.
europepmc   +1 more source

Young children's right to be heard on the quality of their education: Addressing potential misunderstandings in the context of early childhood education

British Educational Research Journal, EarlyView.
Abstract In early childhood education many researchers and professionals across the world have embraced the United Nations Convention on the Rights of the Child's requirement to include young children in decision‐making. In the context of ongoing discussion about young children's capacity to share their views and opinions about matters affecting them ...
Laura Lundy, Colette Murray, Kylie Smith, Carmel Ward   +3 more
wiley   +1 more source

Clinical perspective on management of key adverse events with sacituzumab govitecan. [PDF]

Oncologist
Tolaney SM, Sonpavde GP, Tarantino P, Lustberg MB, Rugo HS.   +4 more
europepmc   +1 more source